We conclude that beta-blocking drugs are generally safe to use in insulin-treated diabetics and that hypoglycaemic unconsciousness resulting from their use is rare. Whether selectivity confers any real advantage remains uncertain. It is unnecessary to deny diabetics the therapeutic benefit of beta-blocking drugs.

We thank Dr D A Pyke, consultant physician to the diabetic department, for his help and encouragement in the production of this paper. DL is supported by the MRC.

Requests for reprints should be sent to AHB.

References

- ¹ Kotler MN, Berman L, Rubenstein AH. Hypoglycaemia precipitated by propranolol. *Lancet* 1966;ii:1389-90.
- ² Malins J. Clinical diabetes mellitus. London: Eyre and Spottiswoode, 1968:434-5.
- ³ Sussman KE, Crout JR, Marble A. Failure of warning in insulin-induced hypoglycaemic reactions. *Diabetes* 1963;12:38-45.
- ⁴ Strom L. Propranolol in insulin-dependent diabetes. *N Engl J Med* 1978; 299:487.
- ⁵ Viberti GC, Stimmler M, Keen H. The effect of oxprenolol and metoprolol on the hypoglycaemic response to insulin in normals and insulin dependent diabetics. *Diabetologia* 1978;15:278.
- ⁶ Passa P, Bouvier P, Assan R, Canivet J. Effects of acebutalol (cardio-selective beta-blocker) on insulin-induced hypoglycaemia in diabetic patients. *Diabetologia* 1977;13:424.
- ⁷ Deacon SP, Karunanayake A, Barnett D. Acebutalol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics. *Br Med J* 1977;iii:1255-7.
- ⁸ Lager I, Blohme G, Smith U. Effects of cardioselective and non-selective β -blockade on the hypoglycaemic response in insulin-dependent diabetics. *Lancet* 1979;ii:458-62.
- ⁹ Abramson E, Arky R, Woeber K. Effects of propranolol on the hormonal and metabolic response to insulin-induced hypoglycaemia. *Lancet* 1966;ii:1386-8.
- ¹⁰ Deacon S, Barnett D. Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. *Br Med J* 1976;iii:272-3.

(Accepted 1 February 1980)

Altered haemorheology in oral-contraceptive users

PETER C BUCHAN, HAMISH N MACDONALD

Summary and conclusions

The haemorheological profile of the menstrual cycle was determined in 12 women who did not take oral contraceptives and compared with that in two groups of women ($n = 8$ and $n = 30$) who had been taking oral contraceptives for at least six months. Packed cell volume, platelet count, erythrocyte deformability, plasma fibrinogen concentration, and plasma and whole-blood viscosity varied cyclically throughout the menstrual cycle in the 12 non-users.

This variation was abolished by the use of oral contraceptives, and the values of these indices were raised by an amount likely to predispose to thrombosis.

Introduction

The association between arteriovenous thromboembolism and use of oral contraceptives is well established^{1,2} and has stimulated investigation into possible causative mechanisms. Contraceptive steroids increase the concentrations of many coagulation factors and reduce that of antithrombin III,³⁻⁵ increase platelet adhesiveness,⁶ and reduce venous flow velocity by increasing venous distensibility⁷ and whole-blood viscosity.⁸⁻¹⁰ All of these effects increase the risk of thromboembolism, and a full understanding of them must be based on a sound appreciation of the physiological background on which they are imposed. Little attention, however, has as yet been paid to the changes in haemorheological indices in the menstrual cycle. We have determined these changes in both users and non-users of oral contraceptives.

Patients and methods

Twenty women had blood taken at the same time of day on four occasions one week apart during their menstrual cycle. Twelve were taking no medication, and eight had been taking an oral contraceptive containing 30 μ g ethinyloestradiol and 250 μ g norgestrel for at least six months. A further 30 women who had been taking the same oral contraceptive for at least six months gave one blood sample between the seventh and twenty-first day of their cycle. All of the women were healthy volunteers, aged from 22 to 34 years, who did not smoke.

Packed cell volume and platelet count were measured with a Coulter Counter S, plasma fibrinogen concentration according to the method of Ratnoff and Menzie,¹¹ erythrocyte deformability by a microfiltration method,¹² and plasma and whole-blood viscosity with a Deer Rheometer at a shear stress of 0.057 N/m² (0.57 dynes/cm²) at 37°C.

Serial data were analysed using paired t tests on the mean differences between stages and cross-sectional data analysed using Student's t tests.

Results

The table shows the mean values of all indices in users and non-users of oral contraceptives and the significances of the differences between the means for adjacent stages in each group.

Packed cell volume rose to a peak at ovulation, remained high in the luteal phase, and fell at menstruation in the women who were not taking oral contraceptives. In the women taking oral contraceptives this variability was abolished. Comparing the cross-sectional data from the 30 contraceptive users with data from each stage of the cycle in non-users, the mean packed cell volume was significantly higher in the contraceptive users than in the non-users for all stages (days 1-7, $p < 0.01$; 12-16, $p < 0.05$; 18-21, $p < 0.01$; and 26-28, $p < 0.05$).

Platelet count rose to a peak at ovulation, started to fall before menstruation, and continued to fall during menstruation in non-users. In contraceptive users the count remained steady throughout the cycle, and in the cross-sectional study the mean platelet count was significantly higher in contraceptive users than in non-users on days 1-7 ($p < 0.01$) and 26-28 ($p < 0.01$).

Plasma fibrinogen concentration in non-users rose to a peak just before menstruation and fell after the onset of menstruation but was otherwise constant. In contraceptive users the concentration remained constant during the 21 days of treatment and then fell slightly but

Department of Obstetrics and Gynaecology, St James's University Hospital, Leeds LS9 7TF

PETER C BUCHAN, BSC, MRCOG, senior registrar

HAMISH N MACDONALD, PHD, FRCOG, consultant obstetrician and gynaecologist

Mean (SE in parentheses) rheological indices in one group of non-users and in two groups of users of oral contraceptives

Indices	Days of cycle									
	Non-users (n = 12)				Users (n = 8)				Users (n = 30)	
	1-7	12-16	18-21	26-28	1-7	12-16	18-21	26-28	7-21	
Packed cell volume	0.382* (0.005)	0.397† (0.006)	0.390 (NS) (0.007)	0.399 (NS) (0.005)	0.407 (NS) (0.008)	0.405 (NS) (0.007)	0.405 (NS) (0.008)	0.404 (NS) (0.009)	0.417 (0.008)	
Platelet count (× 10 ⁹ /l)	241‡ (8)	273* (9)	272 (NS) (9)	259‡ (8)	270 (NS) (7)	278 (NS) (7)	282 (NS) (8)	279 (NS) (8)	278 (8)	
Plasma fibrinogen (g/l)	2.40† (0.09)	2.45 (NS) (0.08)	2.35 (NS) (0.08)	2.64† (0.10)	2.72 (NS) (0.09)	2.80 (NS) (0.08)	2.82 (NS) (0.08)	2.73† (0.10)	2.79 (0.17)	
Erythrocyte deformability index	0.776 (NS) (0.047)	0.783 (NS) (0.075)	0.907‡ (0.007)	0.756† (0.054)	0.861 (NS) (0.064)	0.647† (0.048)	0.788 (NS) (0.066)	0.956‡ (0.059)	0.772 (0.092)	
Plasma viscosity (mPa s)	1.74 (NS) (0.024)	1.69 (NS) (0.023)	1.68 (NS) (0.025)	1.74‡ (0.023)	1.75 (NS) (0.033)	1.78 (NS) (0.031)	1.76 (NS) (0.030)	1.71 (NS) (0.049)	1.77 (0.022)	
Whole-blood viscosity (mPa s)	9.13* (0.375)	11.05 (NS) (1.230)	10.01 (NS) (1.170)	12.63‡ (0.88)	11.24 (NS) (0.790)	10.62 (NS) (0.717)	12.48 (NS) (1.830)	10.49 (NS) (0.837)	11.90 (1.210)	

Statistical comparisons made with paired *t* test.

Difference between mean marked and mean of preceding stage significant at: **p* < 0.001, †*p* < 0.01, ‡*p* < 0.05.

NS = Not significant.

Conversion: SI to traditional units—Packed cell volume: 0.01 = 1%. Platelets: 10⁹/l = 1000/mm³. Fibrinogen: 1 g/l = 100 mg/100 ml. Viscosity: 1 mPa s = 1 cP.

significantly during the seven days without treatment. The 30 contraceptive users had a significantly higher mean plasma fibrinogen concentration than non-users on days 1-7 (*p* < 0.01), 12-16 (*p* < 0.01), and 18-21 (*p* < 0.01).

Erythrocyte deformability in non-users remained constant during the follicular phase, rose to a peak in the early luteal phase, and fell to its lowest value before menstruation. In contraceptive users erythrocyte deformability was at its lowest in mid-cycle and at its highest just before menstruation. The 30 contraceptive users had a significantly lower mean erythrocyte deformability index than the non-users only on days 18-21 (*p* < 0.05).

Plasma viscosity fell slowly in the follicular phase and rose to a peak just before menstruation in non-users. The value was constant in contraceptive users and was significantly higher than in non-users on days 12-16 (*p* < 0.05) and 18-21 (*p* < 0.05).

Whole-blood viscosity in non-users was constant throughout the follicular and early luteal phases, rose to a peak before menstruation, and fell sharply with its onset. In contraceptive users this variability was abolished, and the mean whole-blood viscosity was significantly higher than in non-users on days 1-7 (*p* < 0.01) and 18-21 (*p* < 0.05).

Discussion

The variations in the indices that we have measured are in general agreement with the few studies of individual indices that have been measured in the menstrual cycle¹³⁻¹⁷ and show the effect of the changing concentrations of oestrogen and progesterone. When the effect of oral contraceptives on these indices is investigated the timing of sample collection is important. Meade *et al*² failed to show any effect of oral contraceptives on platelet count using large, randomly sampled groups, whereas Ygge *et al*¹⁸ showed an increase in platelet count with oral-contraceptive use when, as in our study, sample timing was the same in contraceptive users and controls. Similarly Oski *et al*¹⁹ showed a reduction in erythrocyte deformability in oral-contraceptive users with matched sample timing, whereas Leonhardt *et al*⁹ found no reduction with oral-contraceptive use with random sample timing. In none of the published studies has a comparison been made between the values of haemorheological indices in oral-contraceptive users and the various stages of the spontaneous menstrual cycle. Raised packed cell volume, platelet count, plasma fibrinogen concentration, and whole-blood viscosity have been reported in oral-contraceptive users,⁸⁻¹⁰ but it has not been noted that during the premenstrual phase of the spontaneous cycle these indices are raised to similar values as those found throughout the cycle in oral-contraceptive users. Thus the increased risk of thromboembolism associated with oral contraceptives of the type studied cannot be attributed to unusual values of haemorheological factors. Treatment with oral contraceptives, however, abolished the cyclical changes in all the indices measured. This loss of variability combined with small but significant increases, seen also in pregnancy²⁰ with its higher incidence of thromboembolism, may cause sufficient venous stasis and increased

coagulability of blood to be responsible for the increased incidence of thromboembolism in oral-contraceptive users.

We thank Prof D C A Bevis for the use of the facilities of his department, and the nurses, medical students, and doctors who volunteered to participate in the study.

References

- Vessey MP, Mann JI. Female sex hormones and thrombosis. *Br Med Bull* 1978;**34**:157-62.
- Meade TW, Brozovic M, Chakrabarti R, Howarth DJ, North WRS, Stirling Y. An epidemiological study of the haemostatic and other effects of oral contraceptives. *Br J Haematol* 1976;**34**:353-4.
- Dugdale M, Masi AT. Hormonal contraception and thrombo-embolic diseases: effects of the oral contraceptives on haemostatic mechanisms. A review of the literature. *J Chronic Dis* 1971;**23**:775-90.
- Kaulla von KN. Oestrogens and blood coagulation. *Triangle* 1976;**15**:9-17.
- Poller L. Oral contraceptives, blood clotting and thrombosis. *Br Med Bull* 1978;**34**:151-6.
- Zahavi J, Dreyfuss F, Kalef M, Soferman N. Adenosine diphosphate-induced platelet aggregation in healthy women with and without a combined and sequential contraceptive pill. *Am J Obstet Gynecol* 1973;**117**:107-13.
- Goodrich SM, Wood JE. Peripheral venous distensibility and velocity of venous blood flow during pregnancy or during oral contraceptive therapy. *Am J Obstet Gynecol* 1964;**90**:740-4.
- Aronson HB, Magora F, Schenker JG. Effect of oral contraceptives on blood viscosity. *Am J Obstet Gynecol* 1971;**110**:997-1001.
- Leonhardt H, Grigoleit HG, Reinhardt I. Auswirkungen von Zigarettenrauch und oralen Kontrazeptiva auf die Plasma und Vollblutviskosität. *Med Welt* 1978;**29**:880-3.
- Lowe GDO, Reavey MM, Forbes CD, Prentice CRM. Increased blood viscosity in young women taking oral contraceptives. *Clin Sci Mol Med* 1979;**56**:21p.
- Ratnoff O, Menzie C. A new method for the determination of fibrinogen in small samples of plasma. *J Lab Clin Med* 1961;**37**:316-20.
- Buchan PC. Evaluation and modification of whole blood filtration in the measurement of erythrocyte deformability in pregnancy and the newborn. *Br J Haematol* 1980 (in press).
- Vellar OD. Changes in haemoglobin concentration and haematocrit during the menstrual cycle. 1. A cross-sectional study. *Acta Obstet Gynecol Scand* 1974;**53**:243-6.
- Pepper H, Lindsay S. Levels of eosinophils, platelets, leukocytes and 17-hydroxycorticosteroids during normal menstrual cycle. *Proc Soc Exp Biol Med* 1960;**104**:145-7.
- Turksoy RN, Phillips LL, Southam AL. Influence of ovarian function on the fibrinolytic enzyme system. I. Ovulatory and anovulatory cycles. *Am J Obstet Gynecol* 1961;**82**:1211-5.
- Merke C, Lundh B. Erythrocyte filterability and heme catabolism during the menstrual cycle. *Ann Intern Med* 1976;**85**:322-4.
- Dintenfass L, Yu JS. Changes in the blood viscosity and the consistency of artificial thrombi in 17-year-old girls during the menstrual cycle. *Med J Aus* 1968;**1**:181-3.
- Ygge J, Brody S, Korsan-Bengsten K, Nilsson L. Changes in blood coagulation and fibrinolysis in women receiving oral contraceptives. *Am J Obstet Gynecol* 1969;**104**:87-98.
- Oski FA, Lubin B, Buchert ED. Reduced red cell filterability with oral contraceptive agents. *Ann Intern Med* 1972;**77**:417-9.
- Buchan PC, Macdonald HN. Clinical rheology in obstetrics and gynaecology. In: Forbes CD, Lowe GDO, Barbenel JC, eds. *Clinical aspects of blood rheology*. Berlin: Springer-Verlag, 1980 (in press).

(Accepted 28 January 1980)